Skip to main content
Premium Trial:

Request an Annual Quote

Molecular Devices Inks Deal with ChanTest for Ion Channel, GPCR Cell Lines

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular Devices will distribute ChanTest's portfolio of ion channel and GPCR cell lines under a non-exclusive deal announced today.

As part of the deal, Molecular Devices will also sell ChanTest's cell optimization services to Molecular Devices' customers worldwide using its PatchXpress 7000A, IonWorks Quattro, IonWorks Barracuda, and FLIPR Tetra systems.

Based in Cleveland, ChanTest has more than 145 ion channel and 110 GPCR cell lines

In a statement, Mark Verheyden, president of Sunnyvale, Calif.-based Molecular Devices, said that his firm's customers have been asking for validated cells lines optimized for its systems. "By teaming up with [ChanTest], we are able to provide our customers a complete end-to-end solution for their ion channel and GPCR assays," he said.

Financial and other terms of the deal were not disclosed.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.